WO2000057871A3 - Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof - Google Patents

Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof Download PDF

Info

Publication number
WO2000057871A3
WO2000057871A3 PCT/US2000/008433 US0008433W WO0057871A3 WO 2000057871 A3 WO2000057871 A3 WO 2000057871A3 US 0008433 W US0008433 W US 0008433W WO 0057871 A3 WO0057871 A3 WO 0057871A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
identifying agents
inhibit
nox
Prior art date
Application number
PCT/US2000/008433
Other languages
French (fr)
Other versions
WO2000057871A2 (en
Inventor
Dorothy M Morre
D James Morre
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Priority to AU39306/00A priority Critical patent/AU3930600A/en
Publication of WO2000057871A2 publication Critical patent/WO2000057871A2/en
Publication of WO2000057871A3 publication Critical patent/WO2000057871A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention described herein encompasses methods of preventing or treating disorders caused by oxidative damage by an aging-specific isoform of NADH oxidase (AR-NOX). The invention encompasses methods of assaying, screening, and identifying agents that inhibit AR-NOX, as well as methods using ubiquinone to inhibit the ability of AR-NOX to generate reactive oxygen species. These agents may be formulated into pharmaceutical compositions in the prevention and treatment of disorders caused by oxidative damage.
PCT/US2000/008433 1999-03-30 2000-03-29 Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof WO2000057871A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU39306/00A AU3930600A (en) 1999-03-30 2000-03-29 Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12689499P 1999-03-30 1999-03-30
US60/126,894 1999-03-30

Publications (2)

Publication Number Publication Date
WO2000057871A2 WO2000057871A2 (en) 2000-10-05
WO2000057871A3 true WO2000057871A3 (en) 2002-01-31

Family

ID=22427252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/008433 WO2000057871A2 (en) 1999-03-30 2000-03-29 Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof

Country Status (2)

Country Link
AU (1) AU3930600A (en)
WO (1) WO2000057871A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1307281B1 (en) * 1999-11-25 2001-10-30 Simonelli Giuseppe USE OF UBICHINONE Q10 FOR LOCAL TREATMENT AND PREVENTION OF OPHTHALMOLOGICAL DYPATALOGIES SECONDARY TO PHOTOREFRACTIVE THERAPY,
TWI329513B (en) * 2001-10-12 2010-09-01 Kaneka Corp Use of reduced coenzyme q for lessening oxidative stress
ITRM20010755A1 (en) 2001-12-20 2003-06-20 Simonelli Giuseppe USE OF Q10 QUINONE FOR THE TREATMENT OF EYE DISEASES.
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
TWI322008B (en) 2003-01-31 2010-03-21 Kaneka Corp Fatigue improving agent including reduced coenzyme q10
WO2005034945A1 (en) * 2003-10-11 2005-04-21 Thierry Schwitzguebel Use of norphenazone and coenzyme q for curing arthrose, arthritis and osteoarthritis
TW200524579A (en) * 2003-11-28 2005-08-01 Kaneka Corp Composition for protecting liver functions
US20050226947A1 (en) * 2004-02-04 2005-10-13 Dale Kern Agents for sequestering serum aging factors and uses therefore
WO2006104154A1 (en) * 2005-03-29 2006-10-05 Kaneka Corporation Composition for enhancing expression and activity of protease in liver
WO2009120217A1 (en) * 2008-03-28 2009-10-01 Nu Skin International, Inc. Cosmetic compositions for the inhibition of reactive oxygen species
US20120207862A1 (en) * 2010-09-02 2012-08-16 Morre D James ORAL INHIBITORS OF AGE-RELATED NADH OXIDASE (arNOX), COMPOSITIONS AND NATURAL SOURCES
CA3063916A1 (en) * 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4056613A (en) * 1975-07-21 1977-11-01 Societa Farmaceutici Italia S.P.A. Method of reducing the cardiotoxic side effects of glycosidic anthracyclinones
WO1998033495A1 (en) * 1997-01-31 1998-08-06 Idi Farmaceutici S.P.A. Composition of a dietary product that is effective to combat oxidative stress and cell decay
WO1998035660A1 (en) * 1997-02-11 1998-08-20 Mse Pharmazeutika Gmbh Transdermal, oral and intravenous preparations of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
WO1998035658A2 (en) * 1997-02-12 1998-08-20 Mse Pharmazeutika Gmbh The use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
FR2763850A1 (en) * 1997-06-02 1998-12-04 Slow Age Creations Oral composition for treating cutaneous ageing

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4056613A (en) * 1975-07-21 1977-11-01 Societa Farmaceutici Italia S.P.A. Method of reducing the cardiotoxic side effects of glycosidic anthracyclinones
WO1998033495A1 (en) * 1997-01-31 1998-08-06 Idi Farmaceutici S.P.A. Composition of a dietary product that is effective to combat oxidative stress and cell decay
WO1998035660A1 (en) * 1997-02-11 1998-08-20 Mse Pharmazeutika Gmbh Transdermal, oral and intravenous preparations of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
WO1998035658A2 (en) * 1997-02-12 1998-08-20 Mse Pharmazeutika Gmbh The use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
FR2763850A1 (en) * 1997-06-02 1998-12-04 Slow Age Creations Oral composition for treating cutaneous ageing

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
BEERS M H ET AL: "MERCK MANUAL OF DIAGNOSIS AND THERAPY", CENTENNIAL EDITION,WHITEHOUSE STATION, NJ: MERCK RES. LAB,US, 1999, pages 2503 - 2506, XP002141065, ISBN: 0-911910-10-7 *
BERKOW R ET AL: "MERCK MANUAL OF DIAGNOSIS AND THERAPY", RAHWAY, MERCK & CO,US, 1987, pages 2392, XP002141064 *
CALVANI, M. ET AL: "MITOCHONDRIAL DNA IN HUMAN PATHOLOGY", 1993, RAVEN PRESS LTD., NEW YORK, XP000982106 *
COLES, L. STEPHEN ET AL: "Coenzyme Q-10 and lifespan extension", ADV. ANTI-AGING MED. (1996), 205-215. EDITOR(S): KLATZ, RONALD M. PUBLISHER: LIEBERT, LARCHMONT, N. Y., 1996, XP001011292 *
FOLKERS, KARL: "Relevance of the biosynthesis of coenzyme Q10 and of the four bases of DNA as a rationale for the molecular causes of cancer and a therapy", BIOCHEM. BIOPHYS. RES. COMMUN. (1996), 224(2), 358-361, 1996, XP001009783 *
GENOVA MARIA LUISA ET AL: "Decrease of rotenone inhibition is a sensitive parameter of complex I damage in brain non-synaptic mitochondria of aged rats.", FEBS LETTERS, vol. 410, no. 2-3, 1997, pages 467 - 469, XP000979254, ISSN: 0014-5793 *
HATA H: "IMMUNOLOGICAL RESPONSIVENESS OF TUMOR BEARING HOSTS 1. EFFECTS OF COENZYME Q-10 ON 20 METHYL CHOLANTHRENE CARCINOGENESIS", JOURNAL OF THE KANSAI MEDICAL UNIVERSITY, vol. 33, no. 1, 1981, pages 59 - 72, XP001011284, ISSN: 0022-8400 *
HILDEBRANDT H (ED ): "PSCHYREMBEL KLINISCHES WOERTERBUCH", BERLIN: WALTER DE GRUYTER,DE, vol. ED. 258, 1998, pages 47 - 49, XP002141063, ISBN: 3-11-015676-8 *
IWASA H ET AL: "EFFECT OF COENZYME Q-10 AND COMBINED THERAPY OF COENZYME Q-10 AND FT-207 FTORAFUR FOR MICE BEARING METHA TUMOR 2", JOURNAL OF THE NATIONAL DEFENSE MEDICAL COLLEGE, vol. 7, no. 4, 1982, pages 332 - 339, XP001011283, ISSN: 0385-1796 *
JOLLIET P ET AL: "Plasma coenzyme Q10 concentrations in breast cancer: Prognosis and therapeutic consequences.", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 36, no. 9, 1998, pages 506 - 509, XP001011227, ISSN: 0946-1965 *
KAMIKAWA T ET AL: "EFFECTS OF COENZYME Q-10 ON EXERCISE TOLERANCE IN CHRONIC STABLE ANGINA PECTORIS", AMERICAN JOURNAL OF CARDIOLOGY, vol. 56, no. 4, 1985, pages 247 - 251, XP000978238, ISSN: 0002-9149 *
LENAZ GIORGIO ET AL: "Oxidative stress, antioxidant defences and aging.", BIOFACTORS, vol. 8, no. 3-4, 1998, pages 195 - 204, XP000979637, ISSN: 0951-6433 *
LOCKWOOD K ET AL: "Apparent partial remission of breast cancer in 'high risk' patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10", MOLECULAR ASPECTS OF MEDICINE,GB,PERGAMON PRESS, OXFORD, vol. 15, no. SUPPL, 1994, pages S231 - S240, XP002108766, ISSN: 0098-2997 *
LOCKWOOD, KNUD ET AL: "Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases", BIOCHEM. BIOPHYS. RES. COMMUN. (1995), 212(1), 172-7, 1995, XP001009781 *
MORTENSEN S A ET AL: "LONG-TERM COENZYME Q10 THERAPY: A MAJOR ADVANCE IN THE MANAGEMENT OF RESISTANT MYOCARDIAL FAILURE", DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH,BIOSCIENCE EDIPRINT INC,XX, vol. 11, no. 8, 1985, pages 581 - 583, XP000965535, ISSN: 0378-6501 *
NAGLEY, P. ET A.L.: "MITOCHONDRIAL DNA IN HUMAN PATHOLOGY", 1993, RAVEN PRESS LTD., NEW YORK, XP000982105 *
OGURA R ET AL: "ANTI OXIDATIVE EFFECTS OF VITAMIN B-2 BUTYRATE ON THE CARDIAC MITOCHONDRIAL DISORDERS INDUCED BY ADRIAMYCIN", JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY, vol. 28, no. 4, 1982, pages 329 - 334, XP001011282, ISSN: 0301-4800 *
PORTER T H ET AL: "SYNTHESIS ENZYME INHIBITION AND ANTI TUMOR ACTIVITY OF NEW 1 4 BENZO QUINONE ANALOGS OF COENZYME Q-10", BIOORGANIC CHEMISTRY, vol. 7, no. 3, 1978, EN, pages 333 - 350, XP001011285, ISSN: 0045-2068 *
ROWLAND MICHAEL A ET AL: "Coenzyme Q10 treatment improves the tolerance of the senescent myocardium to pacing stress in the rat.", CARDIOVASCULAR RESEARCH, vol. 40, no. 1, October 1998 (1998-10-01), pages 165 - 173, XP000978237, ISSN: 0008-6363 *
SHERRATT E J ET AL: "MITOCHONDRIAL DNA DEFECTS: A WIDENING CLINICAL SPECTRUM OF DISORDERS", CLINICAL SCIENCE,BIOCHEMICAL SOCIETY AND THE MEDICAL RESEARCH SOCIETY, LONDON,,GB, vol. 92, March 1997 (1997-03-01), pages 225 - 235, XP000943576, ISSN: 0143-5221 *
SUZUKI H ET AL: "EFFECTS OF IMMUNOSTIMULATION WITH OK-432 COENZYME Q-10 OR LEVAMISOLE ON DIMETHYLHYDRAZINE-INDUCED COLONIC CARCINOGENESIS IN RATS", JAPANESE JOURNAL OF SURGERY, vol. 16, no. 2, 1986, pages 152 - 155, XP001011254, ISSN: 0047-1909 *

Also Published As

Publication number Publication date
WO2000057871A2 (en) 2000-10-05
AU3930600A (en) 2000-10-16

Similar Documents

Publication Publication Date Title
WO2005076924A3 (en) Agents for sequestering serum aging factors and uses therefore
WO2006034235A3 (en) Substituted quinoline and quinazoline inhibitors of quinone reductase 2
WO2004052348A3 (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
WO2000057871A3 (en) Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof
WO2003057698A3 (en) Spiroazacyclic compounds as monoamine receptor modulators
WO2005099680A3 (en) Use of treprostinil to treat neuropathic diabetic foot ulcers
EP2332527A3 (en) Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
IS6950A (en) Composition of epothilone analogues and chemotherapeutic agents for the treatment of cell proliferative disorders
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
GB0213612D0 (en) Organic compounds
WO2000023568A3 (en) Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
WO2002103103A3 (en) Fluorine-containing compounds and polymers derived therefrom
WO2004045557A3 (en) Novel lapachone compounds and methods of use thereof
WO2002096360A3 (en) Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
WO2005110469A3 (en) Methods and compositions for reducing oxalate concentrations
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
CA2388674A1 (en) Inhibitors of endo-exonuclease activity for treating cancer
WO2005060960A3 (en) Use of histamine to treat bone disease
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
WO2006116380A3 (en) Plasma or serum fraction for the treatment or prevention of bacterial infections
WO2004009029A3 (en) Compositions and methods for treating and preventing infection
WO2003072053A3 (en) Compounds for treatment of copper overload
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP